A total of @ patients were evaluable for response to sorafenib and @ patients were evaluable for response to S+C / T. Objective response rate ( RR ) was @ % for patients on sorafenib vs. @ % for patients on S+C / T ( p = @ ) ; stable disease was seen in @ % and @ % , respectively .